Zevra Therapeutics is attending #SERGG 2024 conference, July 11-13. Our medical team will present a poster highlighting real-world outcomes from our expanded access program of arimoclomol, in adults with #NPC. More about the meeting: https://bit.ly/3zvHGcB
Zevra Therapeutics’ Post
More Relevant Posts
-
Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate
Argenica Therapeutics Managing Director and CEO Dr Liz Dallimore will provide an update on the Company's Phase 2 clinical trial program in acute ischaemic stroke on Direct Connect webinar, Wednesday July 24 at 10:30am AWST / 12:30pm AEST. Dr Dallimore will also participate in a Q&A with shareholders post presentation. Registration is FREE and webinar is hosted on ZOOM: https://lnkd.in/gYTigpYF Stewart Walters Holly Walters Amanda Ellis Riley Maring Liddy McCall Bruno Meloni Meghan Thomas Emma Waldon #AGN #ArgenicaTherapeutics #Stroke #Phase2 #ClinicalTrial
To view or add a comment, sign in
-
Exciting News! Our CEO, Janet Qi, was recently featured in a Clinical Leader article discussing the FDA advisory committee's critique of Lykos Therapeutics' MDMA studies. Despite the 9-2 vote against the validity of MDMA-assisted therapy trials, this highlights the crucial need for rigorous and well-designed clinical trials in the psychedelic field. At PurMinds, we remain committed to advancing the scientific and clinical understanding of psychedelic compounds. Our focus on meticulous research and innovative formulations, such as our proprietary psilocybin and non-hallucinogenic novel chemical entities, drives us forward. We believe in the potential of psychedelics to revolutionize neurological care and are steadfast in our pursuit of evidence-based therapies. Read the full article to learn more about our perspectives and the future of psychedelic clinical research: link in comments! #PurMinds #Psychedelics #MentalHealth #ClinicalResearch #Innovation #FDA #MDMA #PTSD
To view or add a comment, sign in
-
Breaking News in Biotech: Fulcrum Therapeut to Suspend Losmapimod Development After Phase 3 Trial Miss In a recent announcement, Fulcrum Therapeutics (Nasdaq: FULC) revealed that its Phase 3 REACH trial for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD) did not achieve its primary endpoint. The trial, involving 260 patients, assessed the drug’s impact on reachable workspace (RWS) but failed to show significant improvement over placebo. CEO Alex Sapir expressed disappointment, stating, “We plan to suspend the losmapimod program for FSHD.” Despite these results, Fulcrum maintains a robust cash position, with $273.8 million available to advance other promising therapies, including pociredir for sickle cell disease. Chief Medical Officer Dr. Pat Horn noted the trial’s scale and its unique outcome, promising to share full results with FSHD community to aid future research. Fulcrum’s commitment to addressing high unmet medical needs remains strong, with a focus on innovative small-molecule therapies. As of our publication time on 9/12, shares of Fulcrum were down 60%. #pharma #biotech #fulcrum #drugdevelopment $FULC
To view or add a comment, sign in
-
Discounts for the Neuromodulation Summit 2024 expire this Friday! 📢 Check out the full event guide now: https://ter.li/rw1ht3 This exclusive conference is industry’s must-attend meeting to join the community of 80+ experts in neuromodulation to share crucial insights into: ✅ How the CDRH is accelerating patient access to innovation ✅ How to overcome regulatory and clinical challenges to receive funding ✅ How the adoption of invasive and non-invasive devices differs ✅ How to choose which submission type is the best first step Joined by the likes of FDA, LivaNova, Axonics, Inc., Cognito Therapeutics, Inc., Neuspera Medical Inc., ClearPoint Neuro, Inc. and many more - this is not one to miss! Save up to $400 on your pass and join them in Boston this June: https://ter.li/wummg3
To view or add a comment, sign in
-
On Tuesday, February 6, Gilead Sciences held its Q4 2023 earnings call (press release: https://bit.ly/4bqxwZ7 / presentation: https://bit.ly/49usOYL) highlighting that the #Yescarta (#CD19 CAR-T) sales decreased Q0Q while #Tecartus (#CD19 CAR-T) revenue showed a slight increase. Additionally, the company delayed the readout from Yescarta’s Ph2 ZUMA-24 (https://bit.ly/3OzMsdO) to H2 2024, with results from anito-cel’s (formerly CART-ddBCMA; #BCMA CAR-T) Ph2 iMMagine-1 trial (https://bit.ly/3Oxbfiw) also anticipated in the second part of the year. Finally, Gilead disclosed that the enrollment of the first patient in anito-cel’s Ph3 trial in early-line MM is expected in H2 2024. Celltelligence provides insights on Gilead’s #celltherapy revenue decrease, while discussing the plans of the company to try to bring their cell therapies to the community centers: https://bit.ly/CT-855849
To view or add a comment, sign in
-
Happy World Theranostics Day! At AtomVie Global Radiopharma (AtomVie), we are passionate about transforming patients' lives with high-quality radiopharmaceuticals. Theranostics combine therapeutics and diagnostics, offering personalized treatment and marking a significant milestone in modern healthcare. Tap the 'like' button if you're excited about the future of theranostics, and feel free to share your experiences or questions in the comments below. Let's raise awareness and embrace the growing field of theranostics together! #WorldTheranosticsDay #AtomVieGlobalRadiopharma #Radiopharmaceuticals #NuclearMedicine #PersonalizedMedicine
To view or add a comment, sign in
-
Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica
To view or add a comment, sign in
-
New partnership announcement coming out of CincyTech portfolio company Enable Injections, Inc.! Enable Injections and Serina Therapeutics, Inc. are teaming up to revolutionize Parkinson's Disease treatment. 🧠💉 Their recent agreement aims to develop SER-252 in combination with enFuse, offering advanced solutions for those battling Parkinson's Disease. 🔍 SER-252, coupled with enFuse technology, promises groundbreaking advancements in Parkinson's treatment. With enhanced delivery methods, this collaboration could significantly improve patients' quality of life. Read more about this game-changing partnership here: https://lnkd.in/e4KYSJdZ #ParkinsonsDisease #MedicalInnovation #HealthcareAdvancements
To view or add a comment, sign in
-
Did you catch our latest BioBreakthroughs yesterday? We won't even tell you it's a must listen, cause you know it is. Marcio Souza, CEO of Praxis Precision Medicines, Inc., shares insights on revolutionizing CNS drug development. Praxis is paving the way for groundbreaking CNS (central nervous system) treatments with their patient-centric and genetics-inspired approach. Thanks to Sage Growth Partners for being our partner in this episode. #CNSDrugDevelopment #BiotechInnovation #SoHCPodcasts
To view or add a comment, sign in
-
Struggling with the “Double-blinded placebo-controlled randomized controlled clinical trial for patients with Anal Intraepithelial Neoplasia (AIN),” Frantz Viral Therapeutics, a joint venture between Georgetown University Medical Center and Frantz Medical Group, faced numerous challenges while dealing with the trial phases. Moving ahead, they reached out to us with their concern over the ongoing challenges and sought help through Jeeva Clinical Trials Inc.'s eclinical solutions to accelerate their research. Learn how we accepted the challenges and, through our efficient and innovative solutions, assisted them in fulfilling their objectives from this case study: https://hubs.la/Q02gg2dj0 #RCT #clinicaltrials #AIN #healthtech #casestudy #randomizedclinicaltrial
To view or add a comment, sign in
10,450 followers